EX-10.19(ii)



 Exhibit 10.19(ii) 

FIRST AMENDMENT TO TECHNOLOGY LICENSE AGREEMENT 

THIS FIRST AMENDMENT TO TECHNOLOGY LICENSE AGREEMENT (the “License Amendment”) is made and entered into as of February 18, 2015
by and between THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (“UT’’), a corporation vested with the government, management and control of the University of Toronto by the University of Toronto Act, 1971 and having offices
at Banting Institute, 100 College Street, Suite 413, Toronto, Ontario, Canada, M5G 1L5 and PROTAGENIC TIIERAPEUTICS, INC. a corporation incorporated under the laws of Delaware and having a principal place of business at 149 5th Avenue, Suite
500, New York, NY 10010, U.S.A. (“Licensee”). 
 BACKGROUND: 

 

	 	A.	The Licensee and the University of Toronto Innovations Foundation (“UTIF”) entered into a technology license agreement effective July 21, 2005 (“License Agreement”).


  

	 	B.	Effective May 1, 2006, UTIF ceased to operate its business and it transferred and assigned all of its business and assets to UT and the License Agreement continued under the same terms and conditions aside from UT
replacing UTIF in said License Agreement. 

  

	 	C.	UT and Licensee entered into a sponsored research agreement dated December 14, 2004, as amended May 31, 2005; December 11, 2006; April 16, 2007; March 17, 2008; March 18,
2009; February 1, 2011; February 21, 2011; May 18, 2011; April 1, 2012; and April 1, 2013 and may enter into additional sponsored research agreements (collectively the “Research Agreement”).


  

	 	D.	UT and Licensee wish for improvements (as defined in the License Agreement and listed under Schedule A hereto), created by David Lovejoy and/or other research participants under the Research Agreement while employed by
UT, to be included in the License. 

  

	 	E.	UT and Licensee wish to amend the License Agreement in accordance with the conditions hereof. 

 NOW
THEREFORE, the Parties hereto agree to further amend and revise the License Agreement as follows:  
 All capitalized terms not defined herein
shall have the same meaning ascribed to such terms as set out in the License Agreement. 








	1.	All references to the University of Toronto Innovations Foundation and “UTIF” are hereby deleted and replaced with The Governing Council of the University of Toronto and “UT” respectively.


 2. Section 1.1 -Definitions. 

The definition of “Improvements” is hereby deleted in its entirety and replaced with the following:  

“Improvements” means any and all improvements, variations, updates, modifications or enhancements to the Technology (including
without limitation any related Intellectual Property Rights) which are developed under the terms of a research agreement dated December 14, 2004, as amended May 31, 2005; December 11, 2006; April 16,
2007; March 17, 2008; March 18, 2009; February 1, 2011; February 21, 2011; May 18, 2011; April 1, 2012; and April 1,2013, and under the terms of any other sponsored research agreement
designated in same as being added by reference to Schedule B of this Agreement and this Agreement shall be deemed to be amended accordingly to incorporate all such sponsored research agreements as a Research Agreement by reference between Licensee
and The Governing Council of the University of Toronto. 
 The definitions of “Phase I End”, “Phase II End” and
“Phase III End” are hereby deleted in their entirety and replaced with the following:  
 “Phase I
End” means approval by the FDA or other applicable regulatory authority to commence Phase II Clinical Trials of each Licensed Product as such trials are described in 21 C.F.R. 312.2 l(b); 

“Phase II End” means approval by the FDA or other applicable regulatory authority to Commence Phase III Clinical Trials of
each Licensed Product as such trials are described in 21 C.F.R.3 12.21(c); 
 “Phase III End” means Regulatory
Approval of each Licensed Product; 
 The definition for “University” is hereby deleted in its entirety and replaced with the
following:  
 “University” means The Governing Council of the University of Toronto. 

3. Section 2.1(a) -Grant of License for Technology 

Section 2.1 (a) is hereby deleted in its entirety and replaced with the following; 

(a) an exclusive license within the Territory and within the Field of Use to develop, make, have made, use, sell, offer for sale and import the Technology and
Licensed Products under all Owners’ and/or David Lovejoy’s and or UT rights, title and interest in the Technology and Licensed Products; and 







 4. Section 3.1 -Royalty 

Section 3.1(f) is added as follow: 
 f) For clarity, Upfront
Sub-License Fees shall exclude any and all research and development payments, reimbursements, loans and equity investments in the Company and payments made in respect of a collaboration agreement or acquisition agreement, whether such payments are
for research milestones or otherwise, supply of product and similar arrangements. 
 5. Section 4.1 -Ownership 

Section 4.1 is hereby deleted in its entirety and replaced with the following: 

All Intellectual Property Rights in all aspects and parts of the Technology and Improvements shall be exclusively owned by the Owners, and/or David Lovejoy
and/or the UT as the case may be and nothing herein shall serve to, or should be construed to transfer any Intellectual Property Rights whatsoever in the Technology or Improvements except to the extent that any such Intellectual Property Rights are
developed solely by the Licensee (with or without a third party) in which case the Licensee shall own or co-developed with the Licensee, in which case the Licensee shall have co-ownership rights in same as applicable. 

6. Section 4.3 -Patents and Patent Applications. 

Section 4.3 (a) is hereby deleted in its entirety and replaced with the following: 

 

	 	(a)	Licensee, in the name of the Owners, and/or David Lovejoy and/or UT (and as the case may be the Licensee if a joint developer) as the case may be, as assignee, shall file, prosecute and maintain the Patents. Licensee
shall determine in which countries to pursue patent applications. In the event that Licensee elects not to continue prosecution in any country, UT may, at its sole discretion, file such patent or continue such prosecution in that country at its own
expense. In such cases, any patents arising from such applications shall be excluded from the grant of rights under Section 2.1 herein for said country. 


Section 4.3 (e) is hereby deleted in its entirety and replaced with the following: 

 

	 	(e)	Licensee undertakes to keep UT reasonably advised of the progress of prosecution and of any actions Licensee proposes to take or has taken in connection with the prosecution or maintenance of the Patents. Licensee shall
provide UT with copies of correspondence and all actions issued by patent authorities and shall take into account any comments, remarks or suggestions UT may promptly provide to Licensee in writing at least ten (10) days prior to any due date
established by Licensee for preparation of a response or amendment, and in all cases thirty (30) days prior to any patent office due date. 








 7. Section 4.4 -Improvements 

Section 4.4 is hereby amended by replacing the phrase at the third line, “the name of the Owners, or David Lovejoy” with the name of the Owners
and/or David Lovejoy and/or UT (and, as the case may be) the Licensee if a joint developer)” 
 8. Section 7 -Notices. 

Section 7.3 (a) is hereby deleted and replaced with the following: 
  

	(a)	In the case of a notice to Licensee: 

 Protagenic Therapeutics, Inc. 

149 5th Avenue, 
 Suite 500, New
York, NY 10010 
 U.S.A. 

Attention: Robert Ziroyan, PhD, MSc 

E-mail: robert.ziroyan@me.com  

With a copy to: 
 Gowlings
Lafleur Henderson LLP 
 1 First Canadian Place 

100 King Street West Suite 1600 

Toronto, Ontario M5X 1G5 
 Canada

 Attention: Anita Nador 

E-mail: anita.nador@gowlings.com 

Section 7.3 (b) is hereby deleted and replaced with the following: 
  

	(b)	In the case of a notice to UT: 

 Innovations and Partnerships Office 

Banting Institute, 100 College Street, Suite 413 

Toronto, Ontario M5G lL5 
 Canada

 Attention: Jennifer Fraser 

Director, Innovations 
 E-mail:
jen.fraser@utoronto.ca 
  

	9.	Schedule “A” is hereby amended by including the additional Improvements (Confidential Intellectual Property Disclosures & related Patents and Patent Applications) under the Schedule. 










	10.	Schedule “B” is hereby amended by incorporating by reference the 2012 and the 2013 Sponsored Research Agreements to the Schedule and any other Research Agreement designated in same as being added by reference
to Schedule B of the License Agreement between Licensee and The Governing Council of the University of Toronto. 

  

	11.	Except as set out herein, this License Amendment shall not amend or modify any other provision within the License Agreement. 

  

	12.	This License Amendment shall be governed by the laws of the Province of Ontario and the federal laws of Canada applicable in the Province of Ontario 


IN WITNESS OF WHICH the Parties hereto have executed this First Amendment. 
  

							
	PROTAGENIC THERAPEUTICS, INC.	  	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
				
	By:	  	 /s/ Robert Ziroyan
	  	By:	  	 /s/ Jennifer Fraser

	Name:	  	Robert Ziroyan, PhD, MSc	  	Name	  	Jennifer Fraser
	Title:	  	Chief Operating Officer, President	  	Title:	  	Director, Innovations








 SCHEDULE A 

Additional Improvements 
 Project Ref:
P1323 
 Copies of listed Invention Disclosures Attached 
  

											
	 S.No.
	  	 Confidential
Invention
Disclosure
Number
	  	 Date of
Disclosure
	  	 Named
Internal
Inventors
	  	 Title of Disclosure
	  	 Date of
Assignment to
Inventors

	1.	  	10002701	  	Jan 16, 2014	  	David Alan Lovejoy	  	Treatment of Insulin-Resistant Hyperglycemia by Teneurin C-Terminal Associated Peptide-1	  	Feb 18, 2015
	2.	  	10002574	  	Mar 27, 2013	  	David Alan Lovejoy; Chand Dhan	  	Treatment of Human male Infertility by Use of Teneurin C-Terminal Associated Peptide (TCAP- 1) Administration	  	March 3, 2015









			
	



	 	UNIVERSITY OF TORONTO
	 	CONFIDENTIAL INTELLECTUAL PROPERTY DISCLOSURE
	 	Banting Institute, Room 413
	 	100 College Street, Toronto, ON M5G 1L5
	 	Tel: (416) 978-7833 Fax: (416) 978-5821 email: ip.officer@utoronto.ca

 1. Title of Invention: Treatment of insulin-resistant hyperglycemia by teneurin C-terminal associated peptide-1
administration 
 2. a) University of Toronto Inventors Individuals intimal to the University who have made an inventive contribution to
this Invention i.e. faculty, students, postdocs, staff etc. Attach extra sheet if necessary: 
  

											
	 SURNAME,

GIVEN NAMES
	 	 UNIVERSITY

PERSONNEL
 NO.
	 	 DEPARTMENT

(List any cross
appointments or affiliated
institutions)
	 	 AFFILIATION
	 	 EMAIL ADDRESS
	 	 CONTACT

INFORMATION
 (mailing address

phone, fax)

	 Lovejoy
 David Alan
	 	001012972	 	 Cell and
 Systems

Biology
	 	Professor	 	 David.lovejoy@
 Utoronto.ca
	 	 Tel: cell: 647 999
 2977, home: 905

642 4616
  

Address: 149
 Baker Street,

Stouffville,
 Ontario, L4A

1K6


 b) External Inventors Non-University of Toronto Individuals who have made an inventive contribution to the Invention.
i.e. sponsor employees, academic collaborators, etc. List name, organization and e-mail address. 
 not applicable 

 

			
	 For Research Services use only: 
 Date Received:
JAN 16 2014
	 	 DISCLOSURE REFERENCE NO: 10002701


 Version: 2011.09.08 








	 	c)	Contributors Individuals Internal or external to the University who have not made an Inventive Contribution to this Invention but have made a valuable contribution to the development of the Invention. List
name organization and e-mail address. 

 Protagenic Therapeutics Inc provided the majority of the funding for this project 

Contact: Dr. Robert Ziroyan: rziroyan@protagenic.com 

3. Where did the work leading to this Invention take place? Please be specific 

In vitro studies were conducted in rooms 304, 305 in Ramsay Wright Building at the University of Toronto. Animal studies were conducted in the
Biosciences Support Facility central vivarium at Ramsay Wright. Hormone studies were performed under contract by Rules Based Medicine, a contract research organization (CRO) 

4. Invention Description Please provide a description of this Invention for evaluation, highlighting its novel or patentable aspects. Attach a separate
sheet if necessary. 
 TCAP-l is a 41 amino acid peptide derived from a natural protein (teneurin) found in the human reproductive organs and
other tissues. It acts to regulate cell metabolism via a unique mechanism associated with activation of the dystroglycan complex leading to a signal transduction cascade to increase the number of glucose transporters in the cell membrane thereby
increasing the transport of glucose into the cell. This action leads to significantly higher cellular energy in the form of increased cellular ATP levels. At the organismal level, single doses of TCAP-1 at 300 and 3000 pmoles significantly decrease
blood glucose levels as long as one week later. 
 5. Have there been any prior disclosures (abstracts, presentations, publications) in respect of this
Invention? List them and provide the date each disclosure occurred. 
 Chen C. Song L. de Lannoy L, Xu M, Crosier R, Lovejoy DA
(November. 2013) Insulin independent glucose transport and enhanced neuron metabolism by Teneurin C-terminal Associated Peptide (TCAP)-l Society for Neuroscience. San Diego, USA 

 

	6.	a) How was the work leading to this Invention funded? (I.e. salaries, equipment used, supplies 

 etc.) 

 

					
	 SPONSOR
	  	 PROJECT TITLE
	  	 RIS FUND #

	Protagenic Therapeutics Inc	  	Evidence for the existence of TCAP receptors	  	495550








 b) Was the project/work leading to this Invention subject to any software licence, material
transfer, confidentiality, non-disclosure, collaboration or other agreement, written or oral, not referenced in (a) above? 
 x NO         ̈ YES (please provide details) 
  

	7.	Have any patent applications or other intellectual property protection been filled in respect of this invention? 


 ̈ NO        
x YES (please provide details) 
  

	 	1.	AUSTRALIA: September 2010. Patent Number: (May 2, 2003) 2003221575 Teneurin c-terminal associated peptides (tcap) and methods and uses thereof Inventors: LOVEJOY, David; CHEWPOY, R. Bradley; BARSYTE, Dalia;
ROTZINGER, Susan. 

  

	 	2.	UNITED STATES. August 26, 2011. Patent Number 10/510959. Teneurin c- terminal peptides (TCAP) and uses thereof LOVEJOY, David; CHEWPOY, R. Bradley; BARSYTE, Dalia; ROTZINGER, Susan.


 8. Warranty: 
 I/We the Inventors
listed in Section 2(a), have read, understood and agree to all of the preceding, and declare that all of the Information provided in this disclosure is complete and correct. To the best of our knowledge, all persons who might legally make an
ownership claim in this Invention are identified in Section 2(a) and 2(b). 
  

									
	/s/ David A. Lovejoy	  		  	 	  	 
	Signature	  	Date: 01/14/2014	  		  	Signature	  	
	 Typed Name:
  
	  	David A. Lovejoy	  		  	Typed Name:	  	 
	Signature	  	Date	  		  	Signature	  	Date
	Typed Name:	  		  		  	Typed Name:	  	









			
	



	  	UNIVERSITY OF TORONTO
	  	CONFIDENTIAL INTELLECTUAL PROPERTY DISCLOSURE
	  	Banting Institute, Room 413
	  	100 College Street, Toronto, ON M5G 1 L5
	  	Tel: (416) 978-7833 Fax: (416) 978-5821 email: ip.officer@utoronto.ca

 1. Title of Invention: Treatment of human male infertility by use of teneurin C-terminal associated peptide (TCAP)-1
administration 
 2. a) University of Toronto Inventors Individuals internal to the University who have made an inventive contribution to
this Invention i.e. faculty, students, postdocs, staff etc. Attach extra sheet if necessary: 
  

											
	 SURNAME,

GIVEN
NAMES
	  	 UNIVERSITY

PERSONNEL
 NO.
	  	 DEPARTMENT

(List any cross
appointments or
affiliated
institutions)
	  	 AFFILIATION
	  	 EMAIL ADDRESS
	  	 CONTACT

INFORMATION
 (mailing address

phone, fax)

	 Lovejoy
 David Alan
	  	001012972	  	Cell and Systems Biology	  	Professor	  	David.lovejoy@utoronto.ca	  	 Tel: 647 999 2977
 Dept of Cell
of
 Systems Biology
 Ramsay Wright

Bldg. 25 Harbord
 Street, University of Toronto

						
	 Chand
 Dhan
	  	993001103	  	 Cell and
 Systems

Biology
	  	Ph.D. Graduate	  	 Dhan.chand
 @mail.utoronto.ca
	  	 Tel: 416 209 0826
 Dept. of Cell of Systems
Biology
 Ramsay Wright
 Bldg. 25 Harbord street. University of
Toronto


 b) External Inventors Non-University of Toronto individuals who have made an inventive contribution to the Invention,
i.e. sponsor employees, academic collaborators, etc. List name, organization and email address. 
 not applicable 

c) Contributors Individuals internal or external to the University who have not made an inventive contribution to this Invention but have made a
valuable contribution to the development of the Invention. List name, organization and e-mail address. 
 Protagenic Therapeutics Inc provided the majority
of the funding for this project 
 Contact: Dr. Robert Ziroyan: rziroyan@protagenic.com 

 

			
	 For Research Services use only:
 Date Received:
Mar 27 2013
	 	 DISCLOSURE REFERENCE NO: 10002574










	3.	Where did the work leading to this Invention take place? Please be specific. 

 In vitro
studies were conducted in rooms 304, 305 in Ramsay Wright Building at the University of Toronto. Animal studies were conducted in the Biosciences Support Facility central vivarium at Ramsay Wright. Hormone studies were performed under contract by
Rules Based Medicine a contract research organization (CRO). 
  

	4.	Invention Description Please provide a description of this Invention for evaluation, highlighting its novel or patentable aspects. Attach a separate sheet if necessary. 


TCAP-l is a 41 amino acid peptide derived from a natural protein (teneurin) found in the human reproductive organs and other tissues. It acts
to regulate cell metabolism via a unique mechanism associated with activation of the dystroglycan complex. In the male reproductive system the teneurin-dystroglycan complex is associated with regions of the testes and epididymis that play a role in
spermatozoa formation, maturation and viability. In vivo studies indicate that synthetic TCAP-l modifies testicular and epididymal morphology increases testes size and increases testosterone production. These effects are consistent with increased
activity of the reproductive system in mate mice. However because the peptide and hormone system is highly conserved in all mammals as well as vertebrates in general, these studies suggest that synthetic TCAP-l has potential to be used to treat some
forms of male infertility in humans as well as other species. 
  

	5.	Have there been any prior disclosures (abstracts, presentations, publications) in respect of this invention? List them and provide the date each disclosure occurred. 


Chand D, Colacci M, Dixon K, Lovejoy DA. (2012). Gonadal characterization of the evolutionary conserved teneurin-dystroglycan system in mouse.
26th Conference of European Comparative Endocrinologists, Zurich, Switzerland (August 2012) 
  

	6.	a) How was the work reading to this Invention funded? (i.e. salaries, equipment used, supplies etc.) 

  

					
	 SPONSOR
	  	 PROJECT TITLE
	  	 RIS FUND #

	Protagenic Therapeutics Inc	  	 Existence for the existence of TCAP
 Receptors
in neurons
	  	457526

  

	b)	Was the project/work leading to this Invention subject to any software licence, material transfer, confidentiality, non-disclosure, collaboration or other agreement, written or oral, not referenced in (a) above
? 


x  NO     ̈  YES (please
provide details) 








	7.	Have any patent applications or other Intellectual property protection been filed in respect of this invention? 


	  	 ̈ NO         x YES (please provide details) 


 

	 	1.	AUSTRALIA: September 2010. Patent Number: (May 2,2003) 2003221575 Teneurin c-terminal associated peptides (tcap) and methods and uses thereof Inventors: LOVEJOY, David; CHEWPOY, R. Bradley; BARSYTE, Dalia; ROTZINGER,
Susan 

  

	 	2.	UNITED STATES. August 26, 2011. Patent Number 10/510959. Teneurin C-terminal peptides (TCAP) and uses thereof. LOVEJOY, David; CBEWPOY, R. Bradley; BARSYTE, Dalia; ROTZINGER, Susan. 


 

	8.	Warranty: 

 I/We. the Inventors listed in Section 2(a) , have read, understood and agree to all of
the preceding, and declare that all of the Information provided in this disclosure is complete and correct. To the best of our knowledge, all persons who might legally make an ownership claim in this Invention are identified in Section 2(a) and
2(b) 
  

									
	/s/ David A. Lovejoy	  		  	/s/ Dan S. Chand
	Signature	  	Date: 03/20/2013	  		  	Signature	  	Date: 03/20/2013
	 Typed Name:
  
	  	David A. Lovejoy	  		  	Typed Name:	  	Dhan S. Chand
	Signature	  	Date	  		  	Signature	  	Date
	Typed Name:	  		  		  	Typed Name:	  	

  







 SCHEDULE A (Continued) 

Status Listing of Patent Applications filed for the Improvements 

 

	
	 TENEURIN C- TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF

	Inventors: LOVEJOY, David; CHEWPOY, R. Bradley; BARSYTE, Dalia; ROTZINGER, Susan

  

																	
	 COUNTRY
	  	REFERENCE#	  	TYPE	  	FILED	  	SERIAL #	  	ISSUED	  	PATENT #	  	STATUS
								
	 UNITED
 STATES
	  	T8476262USP1
 (090931-360625)
	  	OTH	  	05/03/2002	  	60/377,231	  		  		  	EXPIRED
								
	 UNITED
 STATES
	  	T8476262USP2
 (090931-360627)
	  	OTH	  	11/06/2002	  	60/424,016	  		  		  	EXPIRED
								
	WIPO	  	T8476262WO
 (090931-360635)
	  	CEQ	  	05/02/2003	  	PCT/
CA03/00622	  		  		  	ENTERED
 NATIONAL
 PHASE

								
	AUSTRALIA	  	T8476262AU
 (090931-360631)
	  	DCA	  	05/02/2003	  	2003221575	  	09/23/2011	  	2003221575	  	ISSUED
								
	CANADA	  	T8476262CA
 (090931-360629)
	  	DCA	  	05/02/2003	  	2,482,810	  	06/10/2014	  	2,482,810	  	ALLOWED
								
	 EUROPEAN
 PATENT
	  	T8476262EP
 (090931-360633)
	  	DCA	  	05/02/2003	  	03717086.7	  	03/12/2014	  	1499635	  	GRANTED
		
	 COMMENTS:
	  	Validated in France, Germany and Great Britain
 Opposition period is over; no opposition(s)
filed

						
	JAPAN	  	T8476262JP
 (090931-360634)
	  	DCA	  	05/02/2003	  	2004-501444	  	ABANDONED
								
	 UNITED
 STATES
	  	T8476262US
 (090931-360630)
	  	DCA	  	11/01/2004	  	10/510,959	  	01/03/2012	  	8,088,889	  	ISSUED
						
	 UNITED
 STATES
	  	T8476262USCON
 (090931-438501)
	  	CON	  	11/09/2011	  	13/292,849	  	PENDING








 A METHOD FOR INHIBITING NEURAL CELL DEATH 

Inventor: LOVEJOY, David 

															
	 
								
	 COUNTRY
	  	 REFERENCE#
	  	 TYPE
	  	 FILED
	  	 SERIAL #
	  	 ISSUED
	  	 PATENT #
	  	 STATUS

								
	 UNITED
 STATES
	  	 T8476261USP

(090931-370851)
	  	NEW	  	02/15/2006	  	60/773,309	  		  		  	EXPIRED
								
	 UNITED
 STATES
	  	 T8476261US

(090931-387536)
	  	 Non-
 provisional
	  	02/15/2007	  	11/706,376	  		  		  	ABANDONED
	 COMMENTS: This application was abandoned in lieu of filing a Continuation Application


  

															
	 UNITED
 STATES
	  	 T8476261USCON
 (090931-435930)
	  	CON	  	08/03/2011	  	13/197,575	  		  		  	ABANDONED
	 COMMENTS: July 1, 2014 – INSTRUCTIONS TO ABANDON APPLICATION RECEIVED

	 COMMENTS: This application is a Continuation of US application No. 11/706,376


 A METHOD FOR REGULATING NEURITE GROWTH 

Inventor: LOVEJOY, David 
  

															
								
	 COUNTRY
	  	 REFERENCE#
	  	 TYPE
	  	 FILED
	  	 SERIAL #
	  	 ISSUED
	  	 PATENT #
	  	 STATUS

								
	 UNITED
 STATES
	  	 T8476288USP

(090931-372046)
	  	NEW	  	03/21/2006	  	60/783,821	  		  		  	EXPIRED








 METHOD FOR MODULATING GLUCOSE TRANSPORT USING TENEURIN C-TERMINAL ASSOCIATE PEPTIDE (TCAP) 

Inventor: LOVEJOY, David; CHEN, Yani 
  

															
								
	 COUNTRY
	  	 REFERENCE#
	  	TYPE	  	FILED	  	SERIAL #	  	ISSUED	  	PATENT #	  	STATUS
								
	 UNITED
 STATES
	  	T8476302USP	  	Provisional	  	07/18/2014	  	62/026,346	  		  		  	PENDING

 TENEURIN C-TERMINAL ASSOCIATED PEPTIDE (TCAP) AS AN ANTAGONIST OF
LATROTOXIN 
 Inventor: LOVEJOY, David A; D’AQUILA, Andrea L. 
  

															
								
	 COUNTRY
	  	 REFERENCE#
	  	TYPE	  	FILED	  	SERIAL #	  	ISSUED	  	PATENT #	  	STATUS
								
	 UNITED
 STATES
	  	T8476314USP	  	Provisional	  		  		  		  		  	NOT FILED

  







 SCHEDULE B 

Additional Research Agreement (s) 
 Copies
of listed Sponsored Research Agreements Incorporated by Reference 
 Principal Investigator: David Alan Lovejoy 

 

											
						
	 S.No.
	  	 Research Agreement
	  	 Effective Date
	  	 End Date
	  	 Project Title
	  	 Fund Number

						
	1.	  	 Sponsored
 Research

Agreement
	  	Apr 1, 2012	  	March 31, 2013	  	Evidence for existence of TCAP receptors in neurons	  	495550
						
	2.	  	 Sponsored
 Research

Agreement
	  	Apr 1, 2013	  	March 31, 2014	  	Teneurin C-terminal Associated Peptide (TCAP)-mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and
metabolism	  	495550